These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations. Noll B; Wang WL; Gong Y; Zhao J; Kalhor N; Prieto V; Staerkel G; Roy-Chowdhuri S Cancer Cytopathol; 2018 May; 126(5):342-352. PubMed ID: 29499101 [TBL] [Abstract][Full Text] [Related]
3. PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens. Heymann JJ; Bulman WA; Swinarski D; Pagan CA; Crapanzano JP; Haghighi M; Fazlollahi L; Stoopler MB; Sonett JR; Sacher AG; Shu CA; Rizvi NA; Saqi A Cancer Cytopathol; 2017 Dec; 125(12):896-907. PubMed ID: 29024471 [TBL] [Abstract][Full Text] [Related]
4. Cytology cell blocks from malignant pleural effusion are good candidates for PD-L1 detection in advanced NSCLC compared with matched histology samples. Zou Y; Xu L; Tang Q; You Q; Wang X; Ding W; Zhao J; Ren G BMC Cancer; 2020 Apr; 20(1):344. PubMed ID: 32321471 [TBL] [Abstract][Full Text] [Related]
5. EBUS-FNA cytologic-histologic correlation of PD-L1 immunohistochemistry in non-small cell lung cancer. Jug R; Giovacchini CX; Liu B; Green CL; Clarke JM; Mahmood K; Pavlisko EN J Am Soc Cytopathol; 2020; 9(6):485-493. PubMed ID: 32336671 [TBL] [Abstract][Full Text] [Related]
7. Programmed death-ligand 1 expression on direct Pap-stained cytology smears from non-small cell lung cancer: Comparison with cell blocks and surgical resection specimens. Lozano MD; Abengozar-Muela M; Echeveste JI; Subtil JC; Bertó J; Gúrpide A; Calvo A; de Andrea CE Cancer Cytopathol; 2019 Jul; 127(7):470-480. PubMed ID: 31245924 [TBL] [Abstract][Full Text] [Related]
8. Formalin fixation for optimal concordance of programmed death-ligand 1 immunostaining between cytologic and histologic specimens from patients with non-small cell lung cancer. Koomen BM; van der Starre-Gaal J; Vonk JM; von der Thüsen JH; van der Meij JJC; Monkhorst K; Willems SM; Timens W; 't Hart NA Cancer Cytopathol; 2021 Apr; 129(4):304-317. PubMed ID: 33108706 [TBL] [Abstract][Full Text] [Related]
9. PD-L1 testing on the EBUS-FNA cytology specimens of non-small cell lung cancer. Wang G; Ionescu DN; Lee CH; Hiruki T; Myers R; Shaipanich T; Lam S; Melosky B; Zhou C Lung Cancer; 2019 Oct; 136():1-5. PubMed ID: 31421256 [TBL] [Abstract][Full Text] [Related]
10. Comparison of Programmed Death Ligand-1 Immunohistochemical Staining Between Endobronchial Ultrasound Transbronchial Needle Aspiration and Resected Lung Cancer Specimens. Sakata KK; Midthun DE; Mullon JJ; Kern RM; Nelson DR; Edell ES; Schiavo DN; Jett JR; Aubry MC Chest; 2018 Oct; 154(4):827-837. PubMed ID: 30059678 [TBL] [Abstract][Full Text] [Related]
11. Comparative analysis of programmed death ligand 1 expression in paired cytologic and histologic specimens of non-small cell lung cancer. Daverio M; Patrucco F; Gavelli F; Airoldi C; Sciortino G; Chiaramonte C; Rena O; Balbo PE; Boldorini RL Cancer Cytopathol; 2020 Aug; 128(8):580-588. PubMed ID: 32463583 [TBL] [Abstract][Full Text] [Related]
12. Programmed death-ligand 1 testing of lung cancer cytology specimens obtained with bronchoscopy. Stoy SP; Rosen L; Mueller J; Murgu S Cancer Cytopathol; 2018 Feb; 126(2):122-128. PubMed ID: 29053224 [TBL] [Abstract][Full Text] [Related]
13. CT-guided transthoracic needle biopsy for evaluation of PD-L1 expression: Comparison of 22C3 and SP263 assays. Beck KS; Kim SJ; Kang JH; Han DH; Jung JI; Lee KY Thorac Cancer; 2019 Jul; 10(7):1612-1618. PubMed ID: 31237079 [TBL] [Abstract][Full Text] [Related]
14. False-negative programmed death-ligand 1 immunostaining in ethanol-fixed endobronchial ultrasound-guided transbronchial needle aspiration specimens of non-small-cell lung cancer patients. Koomen BM; Vreuls W; de Boer M; de Ruiter EJ; Hoelters J; Vink A; Willems SM Histopathology; 2021 Oct; 79(4):480-490. PubMed ID: 33772818 [TBL] [Abstract][Full Text] [Related]
15. A noninterventional, multinational study to assess PD-L1 expression in cytological and histological lung cancer specimens. Bubendorf L; Conde E; Cappuzzo F; Langfort R; Schildhaus HU; Votruba J; Concha-López Á; Esteban-Rodriguez I; Feng J; Devenport J; Boyiddle C; Morris S; Trunzer K; Kerr KM Cancer Cytopathol; 2020 Dec; 128(12):928-938. PubMed ID: 32721105 [TBL] [Abstract][Full Text] [Related]
16. Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients. Ilie M; Juco J; Huang L; Hofman V; Khambata-Ford S; Hofman P Cancer Cytopathol; 2018 Apr; 126(4):264-274. PubMed ID: 29411536 [TBL] [Abstract][Full Text] [Related]
17. Programmed Death Ligand 1 Testing of Endobronchial Ultrasound-guided Transbronchial Needle Aspiration Samples Acquired For the Diagnosis and Staging of Non-Small Cell Lung Cancer. Smith A; Wang H; Zerbo A; Beaudoin S; Ofiara L; Fiset PO; Benedetti A; Gonzalez AV J Bronchology Interv Pulmonol; 2020 Jan; 27(1):50-57. PubMed ID: 31513030 [TBL] [Abstract][Full Text] [Related]
18. PD-L1 expression in NSCLC: Role of cell blocks and concordance between samples. Ambrosini-Spaltro A; Dubini A; Pieri F; Ravaglia C; Delmonte A; Poletti V Diagn Cytopathol; 2021 Feb; 49(2):303-310. PubMed ID: 33091231 [TBL] [Abstract][Full Text] [Related]
19. Assessment of Programmed Death-Ligand 1 (PD-L1) Immunohistochemical Expression on Cytology Specimens in Non-Small Cell Lung Carcinoma. Hernandez A; Brandler TC; Zhou F; Moreira AL; Schatz-Siemers N; Simsir A Am J Clin Pathol; 2019 Mar; 151(4):403-415. PubMed ID: 30534975 [TBL] [Abstract][Full Text] [Related]
20. Quantitative and qualitative characterization of Two PD-L1 clones: SP263 and E1L3N. Smith J; Robida MD; Acosta K; Vennapusa B; Mistry A; Martin G; Yates A; Hnatyszyn HJ Diagn Pathol; 2016 May; 11(1):44. PubMed ID: 27189072 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]